References
- Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004;93:204-8. https://doi.org/10.1016/j.ygyno.2003.12.029
- Olah KS, Gee H, Blunt S, Dunn JA, Kelly K, Chan KK. Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer 1991;27:1095-9. https://doi.org/10.1016/0277-5379(91)90300-3
- Sampath S, Schultheiss TE, Ryu JK, Wong JY. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys 2010;76:728-34. https://doi.org/10.1016/j.ijrobp.2009.02.077
- Sorbe B, Johansson B. Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas. Int J Oncol 2008;32:1111-7.
- Ferrer F, Sabater S, Farrus B, et al. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 1999;44:47-52. https://doi.org/10.1016/S0360-3016(98)00515-X
- Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44:808-18. https://doi.org/10.1016/j.ejca.2008.01.019
- Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004;58:786-96. https://doi.org/10.1016/S0360-3016(03)01561-X
- Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol 2007;33:91-5. https://doi.org/10.1016/j.ejso.2006.11.012
- Vongtama V, Karlen JR, Piver SM, Tsukada Y, Moore RH. Treatment, results and prognostic factors in stage I and II sarcomas of the corpus uteri. AJR Am J Roentgenol 1976;126:139-47. https://doi.org/10.2214/ajr.126.1.139
- Moskovic E, MacSweeney E, Law M, Price A. Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. Br J Radiol 1993;66:1009-15. https://doi.org/10.1259/0007-1285-66-791-1009
- Tinkler SD, Cowie VJ. Uterine sarcomas: a review of the Edinburgh experience from 1974 to 1992. Br J Radiol 1993;66: 998-1001. https://doi.org/10.1259/0007-1285-66-791-998
- Livi L, Andreopoulou E, Shah N, et al. Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. Clin Oncol (R Coll Radiol) 2004;16:261-8. https://doi.org/10.1016/j.clon.2004.01.010
- Sampath S, Gaffney DK. Role of radiotherapy treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol 2011;25: 761-72. https://doi.org/10.1016/j.bpobgyn.2011.06.004
- Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177-85. https://doi.org/10.1016/j.ygyno.2007.07.070
- Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997;65:493-8. https://doi.org/10.1006/gyno.1997.4676
- Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer 1993;71(4 Suppl):1702-9. https://doi.org/10.1002/cncr.2820710440
- Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998;68:8-13. https://doi.org/10.1006/gyno.1997.4901
- Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986;12:2127-30. https://doi.org/10.1016/0360-3016(86)90011-8
- Park HJ, Kim HJ, Wu HG, et al. The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma. Radiat Oncol J 2011;29:228-35. https://doi.org/10.3857/roj.2011.29.4.228
- Brown L, Petersen I, Haddock M, Lee LJ, Cimbak N, Viswanathan A. Vaginal brachytherapy as the sole radiotherapeutic treatment for stage I carcinosarcoma of the uterus. Brachytherapy 2014;13(Suppl 1):S76-S77.
- Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987;5:840-50. https://doi.org/10.1200/JCO.1987.5.6.840
- Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas: a randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987;23:1477-83. https://doi.org/10.1016/0277-5379(87)90089-7
- Loehrer PJ Sr, Sledge GW Jr, Nicaise C, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol 1989;7:1655-9. https://doi.org/10.1200/JCO.1989.7.11.1655
- Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75. https://doi.org/10.1200/JCO.1993.11.7.1269
- Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45. https://doi.org/10.1200/JCO.1995.13.7.1537
- Pautier P, Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study): a study of the French Sarcoma Group. Ann Oncol 2013;24:1099-104. https://doi.org/10.1093/annonc/mds545
- Gadducci A, Landoni F, Sartori E, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996;62:25-32. https://doi.org/10.1006/gyno.1996.0185
- Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway: a histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54:355-64. https://doi.org/10.1111/j.1365-2559.2009.03231.x
- Blom R, Guerrieri C, Stal O, Malmstrom H, Simonsen E. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998;68:54-61. https://doi.org/10.1006/gyno.1997.4889
- Ayhan A, Aksan G, Gultekin M, et al. Prognosticators and the role of lymphadenectomy in uterine leiomyosarcomas. Arch Gynecol Obstet 2009;280:79-85. https://doi.org/10.1007/s00404-008-0876-0
- Wu TI, Chang TC, Hsueh S, et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol 2006;100:166-72. https://doi.org/10.1016/j.ygyno.2005.08.010
- Sorbe B. Radiotherapy and/or chemotherapy as adjuvant treatment of uterine sarcomas. Gynecol Oncol 1985;20:281-9. https://doi.org/10.1016/0090-8258(85)90209-4
- Salazar OM, Dunne ME. The role of radiation therapy in the management of uterine sarcomas. Int J Radiat Oncol Biol Phys 1980;6:899-902. https://doi.org/10.1016/0360-3016(80)90334-X
Cited by
- An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center vol.12, pp.3, 2015, https://doi.org/10.4274/tjod.33602
- Clinical outcomes of tissue expanders on adjuvant radiotherapy of resected retroperitoneal sarcoma vol.95, pp.28, 2015, https://doi.org/10.1097/md.0000000000004123
- Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review vol.55, pp.4, 2015, https://doi.org/10.1016/j.tjog.2016.04.033
- Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08) vol.27, pp.6, 2016, https://doi.org/10.3802/jgo.2016.27.e58
- Distribution and survival of primary sarcoma in Korea: A single center analysis of 2017 cases vol.14, pp.1, 2015, https://doi.org/10.14216/kjco.18005
- Uterine Sarcomas: Surgical Management, Adjuvant Therapy and Survival Outcome. Experience at Gujarat Cancer and Research Institute vol.17, pp.1, 2015, https://doi.org/10.1007/s40944-018-0247-0
- Hormonal therapy in uterine sarcomas vol.8, pp.4, 2015, https://doi.org/10.1002/cam4.2044
- The Outcomes of Uterine Sarcoma: A Case-series of 5-Years Survey vol.4, pp.3, 2015, https://doi.org/10.30699/jogcr.4.3.120
- The pretreatment erythrocyte sedimentation rate predicts survival outcomes after surgery and adjuvant radiotherapy for extremity soft tissue sarcoma vol.14, pp.1, 2015, https://doi.org/10.1186/s13014-019-1331-z
- Adjuvant Radiotherapy Improved Survival in Stage I to II Low-Grade Endometrial Stromal Sarcoma: A Retrospective Study of 152 Cases vol.10, pp.None, 2015, https://doi.org/10.3389/fonc.2020.608152